OmniAb, Inc. (OABI): Total Assets

Annual figures by period end, from SEC filings.

$300.91M
As of 2025-12-31
$290.26M
As of 2026-06-30
-10.6%
3-year compound annual growth
$421.21M2021-12-31: $304.46M2022-12-31: $421.21M2023-12-31: $375.23M2024-12-31: $325.56M2025-12-31: $300.91M$300.91M
2021-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$300.91M-7.6%2026-03-04, Balance as of period end
2024-12-31$325.56M-13.2%2026-03-04, Balance as of period end
2023-12-31$375.23M-10.9%2025-03-18, Balance as of period end
2022-12-31$421.21M+38.3%2024-03-25, Balance as of period end
2021-12-31$304.46Mn/a2023-03-30, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
OmniAb, Inc. (OABI)2025-12-31$300.91M-7.6%
Foxo Technologies Inc. (FOXO)2025-12-31$44.58M+6.9%
MaxCyte, Inc. (MXCT)2025-12-31$202.51M-15.4%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$10.96M+68.3%
Absci Corp (ABSI)2025-12-31$216.30M+1.3%
NRC Health (NRC)2025-12-31$134.88M+1.8%
iSpecimen Inc. (ISPC)2025-12-31$9.53M+1.9%
OneMedNet Corp (ONMD)2025-12-31$2.15M-42.3%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$31.9K-44.2%

Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗